x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230091
| Product Information | |
|---|---|
| CAS No. | 1352792-74-5 |
| Formula | C20H16N2O2S |
| Molecular Weight | 348.41824 |
| SMILES | CC(C)(SC1=C(C=NC=C1)C2=C3C=CC=CC3=C(C=C2)C#N)C(O)=O |
| Product Description | Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter with an IC50 of 25 nM for inhibiting transport activity of human URAT1. It inhibits the related URAT1 homologs OAT4 and OAT1 with approximately 200-fold lower affinity compared to URAT1 with IC50 values of 5.9 µM and 4.6 µM, respectively. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
